Adverse events and adverse drug reaction in geriatrics. by Jae Gyoon Kim (16426036)

Subjects:

M^pro confers a significant reduction in growth in yeast caused by decreases in a variety of cellular proteins. by Jin Ou (16914305)

Adverse event severity based on age, gender, dose and time to onset. by Louis Okeibunor Odeigah (13250062)

Subjects:

Adverse event categories based on age, gender, dose, and time to onset. by Louis Okeibunor Odeigah (13250062)

Subjects:

Significant variables in decreasing importance for varietal clustering based on Random forest method. by Wilfried Chevalier (10521466)

Spleen PAX5 significantly decreased in APRIL/BLyS blockade treated mice. by Natalie M. Bath (6316517)

Arctigenin decreased proliferation in colorectal cancer cells with no significant effect on normal cells. by Xiang-Fan Chen (13932983)

Cabozantinib significantly decreases tumor volume and prolongs survival in SCNPC PDX models. by Mark P. Labrecque (10011469)

Table1_Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system.XLSX by Xianglin Pan (4441699)

“…Among the factors significantly influencing oxaliplatin-related neurological adverse events, male sex and combination medication decreased the risk of neurological adverse events, while higher cumulative dose increased the risk.…”

Image3_Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system.JPEG by Xianglin Pan (4441699)

“…Among the factors significantly influencing oxaliplatin-related neurological adverse events, male sex and combination medication decreased the risk of neurological adverse events, while higher cumulative dose increased the risk.…”

Table4_Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system.XLSX by Xianglin Pan (4441699)

“…Among the factors significantly influencing oxaliplatin-related neurological adverse events, male sex and combination medication decreased the risk of neurological adverse events, while higher cumulative dose increased the risk.…”

Table2_Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system.XLSX by Xianglin Pan (4441699)

“…Among the factors significantly influencing oxaliplatin-related neurological adverse events, male sex and combination medication decreased the risk of neurological adverse events, while higher cumulative dose increased the risk.…”

Table3_Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system.XLSX by Xianglin Pan (4441699)

“…Among the factors significantly influencing oxaliplatin-related neurological adverse events, male sex and combination medication decreased the risk of neurological adverse events, while higher cumulative dose increased the risk.…”

Image2_Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system.JPEG by Xianglin Pan (4441699)

“…Among the factors significantly influencing oxaliplatin-related neurological adverse events, male sex and combination medication decreased the risk of neurological adverse events, while higher cumulative dose increased the risk.…”

Image1_Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system.JPEG by Xianglin Pan (4441699)

“…Among the factors significantly influencing oxaliplatin-related neurological adverse events, male sex and combination medication decreased the risk of neurological adverse events, while higher cumulative dose increased the risk.…”

Adverse events in the overall population. by Dimuthu Muthukuda (6550692)

Tissue, days post-infection (dpi) and the top 10 most significant genes with increased and decreased expression with valid gene symbols for the response contrasts. by Gillian P. McHugo (8965919)

Adverse events and adverse drug reaction in overall population. by Jae Gyoon Kim (16426036)

Subjects:

Adverse effects of chemotherapy. by Aman Kumar Sah (22453695)

Subjects:

Deletion of <i>Trgal11</i> resulted in a significant decrease in the transcription of cellobiohydrolase and endoglucanase but not β-glucosidase genes. by Fanglin Zheng (4844064)